Y-mAbs Therapeutics, Inc. – NASDAQ:YMAB
Founder-led company
Y-mAbs Therapeutics stock price today
$8.53
+0.52
+6.62%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 2 hours
Y-mAbs Therapeutics stock price monthly change
-35.90%
month
Y-mAbs Therapeutics stock price quarterly change
-35.90%
quarter
Y-mAbs Therapeutics stock price yearly change
+9.29%
year
Y-mAbs Therapeutics key metrics
Market Cap | 362.79M |
Enterprise value | 163.90M |
P/E | -2.79 |
EV/Sales | 1.89 |
EV/EBITDA | -1.01 |
Price/Sales | 3.09 |
Price/Book | 2.45 |
PEG ratio | 0.04 |
EPS | -0.49 |
Revenue | 84.49M |
EBITDA | -24.75M |
Income | -21.66M |
Revenue Q/Q | -1.58% |
Revenue Y/Y | 12.61% |
Profit margin | -190.37% |
Oper. margin | -187.7% |
Gross margin | 87.82% |
EBIT margin | -187.7% |
EBITDA margin | -29.3% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeY-mAbs Therapeutics stock price history
Y-mAbs Therapeutics stock forecast
Y-mAbs Therapeutics financial statements
Average Price Target
$24
Potential upside: 181.35%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 20.75M | -6.30M | -30.37% |
|---|---|---|---|
| Sep 2023 | 20.45M | -7.74M | -37.88% |
| Dec 2023 | 23.36M | -988K | -4.23% |
| Mar 2024 | 19.93M | -6.62M | -33.26% |
| Jun 2023 | 132396000 | 27.71M | 20.93% |
|---|---|---|---|
| Sep 2023 | 128884000 | 28.73M | 22.29% |
| Dec 2023 | 127869000 | 26.88M | 21.02% |
| Mar 2024 | 123315000 | 24.12M | 19.56% |
| Jun 2023 | -4.73M | 0 | 0 |
|---|---|---|---|
| Sep 2023 | -1.33M | 0 | 0 |
| Dec 2023 | -8.03M | 0 | 100K |
| Mar 2024 | -3.47M | 0 | 588K |
Y-mAbs Therapeutics alternative data
| Aug 2023 | 147 |
|---|---|
| Sep 2023 | 147 |
| Oct 2023 | 147 |
| Nov 2023 | 147 |
| Dec 2023 | 147 |
| Jan 2024 | 147 |
| Feb 2024 | 147 |
| Mar 2024 | 100 |
| Apr 2024 | 100 |
| May 2024 | 100 |
| Jun 2024 | 100 |
| Jul 2024 | 100 |
Y-mAbs Therapeutics other data
58.56%
-0.44%
of YMAB is owned by hedge funds
25.28M
-437.43K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Nov 2023 | 290048 | 150000 |
| Dec 2023 | 268008 | 150000 |
| Mar 2024 | 0 | 7293 |
| May 2024 | 0 | 92351 |
| Jun 2024 | 0 | 70722 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | GAD THOMAS director, officer.. | Common Stock | 35,000 | $12 | $420,000 | ||
Sale | BER GERARD director | Common Stock | 722 | $12 | $8,664 | ||
Sale | GAD THOMAS director, officer.. | Common Stock | 35,000 | $12.03 | $421,050 | ||
Option | KRUSE BO officer: EVP, CFO.. | Common Stock | 31,371 | $2 | $62,742 | ||
Option | KRUSE BO officer: EVP, CFO.. | Employee Stock Option (right to buy) | 31,371 | $2 | $62,742 | ||
Sale | KRUSE BO officer: EVP, CFO.. | Common Stock | 31,371 | $12.07 | $378,648 | ||
Option | KRUSE BO officer: EVP, CFO.. | Employee Stock Option (right to buy) | 28,629 | $2 | $57,258 | ||
Option | KRUSE BO officer: EVP, CFO.. | Common Stock | 28,629 | $2 | $57,258 | ||
Sale | KRUSE BO officer: EVP, CFO.. | Common Stock | 28,629 | $12.03 | $344,407 | ||
Sale | GAD THOMAS director, officer.. | Common Stock | 7,351 | $13 | $95,563 |
| Patent |
|---|
Application Filling date: 14 May 2018 Issue date: 25 Jun 2020 |
| Quarter | Transcript |
|---|---|
| Q1 2024 8 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 1 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 14 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 11 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Dr. Claus Juan Møller-San Pedro M.D., Ph.D. (1963) Chief Executive Officer & Director | $960,130 |
| Mr. Thomas Gad (1970) Founder, Chairman, Pres and Head of Bus. Devel. & Strategy | $761,550 |
| Mr. Bo Kruse (1972) Executive Vice President, Sec., Treasurer & Chief Financial Officer | $605,530 |
-
What's the price of Y-mAbs Therapeutics stock today?
One share of Y-mAbs Therapeutics stock can currently be purchased for approximately $8.53.
-
When is Y-mAbs Therapeutics's next earnings date?
Unfortunately, Y-mAbs Therapeutics's (YMAB) next earnings date is currently unknown.
-
Does Y-mAbs Therapeutics pay dividends?
No, Y-mAbs Therapeutics does not pay dividends.
-
How much money does Y-mAbs Therapeutics make?
Y-mAbs Therapeutics has a market capitalization of 362.79M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 29.96% to 84.82M US dollars.
-
What is Y-mAbs Therapeutics's stock symbol?
Y-mAbs Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "YMAB".
-
What is Y-mAbs Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Y-mAbs Therapeutics?
Shares of Y-mAbs Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Y-mAbs Therapeutics's key executives?
Y-mAbs Therapeutics's management team includes the following people:
- Dr. Claus Juan Møller-San Pedro M.D., Ph.D. Chief Executive Officer & Director(age: 62, pay: $960,130)
- Mr. Thomas Gad Founder, Chairman, Pres and Head of Bus. Devel. & Strategy(age: 55, pay: $761,550)
- Mr. Bo Kruse Executive Vice President, Sec., Treasurer & Chief Financial Officer(age: 53, pay: $605,530)
-
Is Y-mAbs Therapeutics founder-led company?
Yes, Y-mAbs Therapeutics is a company led by its founder Mr. Thomas Gad.
-
How many employees does Y-mAbs Therapeutics have?
As Jul 2024, Y-mAbs Therapeutics employs 100 workers.
-
When Y-mAbs Therapeutics went public?
Y-mAbs Therapeutics, Inc. is publicly traded company for more then 6 years since IPO on 21 Sep 2018.
-
What is Y-mAbs Therapeutics's official website?
The official website for Y-mAbs Therapeutics is ymabs.com.
-
Where are Y-mAbs Therapeutics's headquarters?
Y-mAbs Therapeutics is headquartered at 230 Park Avenue, New York, NY.
-
How can i contact Y-mAbs Therapeutics?
Y-mAbs Therapeutics's mailing address is 230 Park Avenue, New York, NY and company can be reached via phone at +64 6 885 8505.
-
What is Y-mAbs Therapeutics stock forecast & price target?
Based on 1 Wall Street analysts` predicted price targets for Y-mAbs Therapeutics in the last 12 months, the avarage price target is $24. The average price target represents a 181.35% change from the last price of $8.53.
Y-mAbs Therapeutics company profile:
Y-mAbs Therapeutics, Inc.
ymabs.comExchange:
NASDAQ
Full time employees:
100
Industry:
Biotechnology
Sector:
Healthcare
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.
230 Park Avenue
New York, NY 10169
New York, NY 10169
CIK: 0001722964
ISIN: US9842411095
CUSIP: 984241109
